Valeritas, which markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes, postponed its IPO on Thursday.
The Bridgewater, NJ-based company was founded in 2006 and booked $13 million in sales for the 12 months ended December 31, 2014. Valeritas initially filed confidentially on 8/8/2014. Piper Jaffray and Leerink Partners were set to be the joint bookrunners on the deal.
